NASDAQ:ALLR - Nasdaq - US0167445008 - Common Stock - Currency: USD
0.9535
+0.01 (+1.44%)
The current stock price of ALLR is 0.9535 USD. In the past month the price decreased by -27.77%. In the past year, price decreased by -99.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Allarity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 5 full-time employees. The company went IPO on 2021-12-21. Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The firm is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. The company has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
ALLARITY THERAPEUTICS INC
24 School St., 2Nd Floor
Boston MASSACHUSETTS US
Employees: 6
Company Website: https://allarity.com/
Investor Relations: https://allarity.com/investors/
Phone: 14014264664
The current stock price of ALLR is 0.9535 USD. The price increased by 1.44% in the last trading session.
The exchange symbol of ALLARITY THERAPEUTICS INC is ALLR and it is listed on the Nasdaq exchange.
ALLR stock is listed on the Nasdaq exchange.
ALLARITY THERAPEUTICS INC (ALLR) has a market capitalization of 4.22M USD. This makes ALLR a Nano Cap stock.
ALLARITY THERAPEUTICS INC (ALLR) currently has 6 employees.
ALLARITY THERAPEUTICS INC (ALLR) has a resistance level at 1.49. Check the full technical report for a detailed analysis of ALLR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALLR does not pay a dividend.
ALLARITY THERAPEUTICS INC (ALLR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-933.21).
The outstanding short interest for ALLARITY THERAPEUTICS INC (ALLR) is 13.25% of its float. Check the ownership tab for more information on the ALLR short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ALLR. The financial health of ALLR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALLR reported a non-GAAP Earnings per Share(EPS) of -933.21. The EPS increased by 99.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -95.31% | ||
ROE | -149.82% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to ALLR. The Buy consensus is the average rating of analysts ratings from 6 analysts.